Cargando…

Branebrutinib (BMS-986195), a Bruton’s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents

The overexpression of P-glycoprotein (P-gp/ABCB1), an ATP-binding cassette (ABC) drug transporter, often contributes to the development of multidrug resistance (MDR) in cancer cells. P-gp mediates the ATP hydrolysis-dependent efflux of a wide range of chemotherapeutic agents out of cancer cells, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Chung-Pu, Murakami, Megumi, Wu, Yu-Shan, Chi, Ya-Chen, Hsiao, Sung-Han, Huang, Yang-Hui, Hung, Tai-Ho, Ambudkar, Suresh V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326665/
https://www.ncbi.nlm.nih.gov/pubmed/34350184
http://dx.doi.org/10.3389/fcell.2021.699571
_version_ 1783731882354016256
author Wu, Chung-Pu
Murakami, Megumi
Wu, Yu-Shan
Chi, Ya-Chen
Hsiao, Sung-Han
Huang, Yang-Hui
Hung, Tai-Ho
Ambudkar, Suresh V.
author_facet Wu, Chung-Pu
Murakami, Megumi
Wu, Yu-Shan
Chi, Ya-Chen
Hsiao, Sung-Han
Huang, Yang-Hui
Hung, Tai-Ho
Ambudkar, Suresh V.
author_sort Wu, Chung-Pu
collection PubMed
description The overexpression of P-glycoprotein (P-gp/ABCB1), an ATP-binding cassette (ABC) drug transporter, often contributes to the development of multidrug resistance (MDR) in cancer cells. P-gp mediates the ATP hydrolysis-dependent efflux of a wide range of chemotherapeutic agents out of cancer cells, thereby reducing the intracellular drug accumulation and decreasing the chemosensitivity of these multidrug-resistant cancer cells. Studies with tyrosine kinase inhibitors (TKIs) in P-gp-overexpressing cells have shown that certain TKIs could reverse MDR mediated by P-gp, while some TKIs are transported by P-gp. In the present work, we explored the prospect of repositioning branebrutinib (BMS-986195), a highly selective inhibitor of Bruton’s tyrosine kinase (BTK), to resensitize P-gp-overexpressing multidrug-resistant cancer cells to chemotherapeutic agents. Our results demonstrated that branebrutinib is capable of reversing P-gp-mediated MDR at sub-toxic concentrations, most likely by directly inhibiting the drug transport function of P-gp. Our findings were supported by the result of branebrutinib stimulating the ATPase activity of P-gp in a concentration-dependent manner and the in silico study of branebrutinib binding to the substrate-binding pocket of P-gp. In addition, we found that branebrutinib is equally cytotoxic to drug-sensitive parental cell lines and the respective P-gp-overexpressing multidrug-resistant variants, suggesting that it is unlikely that the overexpression of P-gp in cancer cells plays a significant role in reduced susceptibility or resistance to branebrutinib. In summary, we discovered an additional pharmacological action of branebrutinib against the activity of P-gp, which should be investigated further in future drug combination studies.
format Online
Article
Text
id pubmed-8326665
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83266652021-08-03 Branebrutinib (BMS-986195), a Bruton’s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents Wu, Chung-Pu Murakami, Megumi Wu, Yu-Shan Chi, Ya-Chen Hsiao, Sung-Han Huang, Yang-Hui Hung, Tai-Ho Ambudkar, Suresh V. Front Cell Dev Biol Cell and Developmental Biology The overexpression of P-glycoprotein (P-gp/ABCB1), an ATP-binding cassette (ABC) drug transporter, often contributes to the development of multidrug resistance (MDR) in cancer cells. P-gp mediates the ATP hydrolysis-dependent efflux of a wide range of chemotherapeutic agents out of cancer cells, thereby reducing the intracellular drug accumulation and decreasing the chemosensitivity of these multidrug-resistant cancer cells. Studies with tyrosine kinase inhibitors (TKIs) in P-gp-overexpressing cells have shown that certain TKIs could reverse MDR mediated by P-gp, while some TKIs are transported by P-gp. In the present work, we explored the prospect of repositioning branebrutinib (BMS-986195), a highly selective inhibitor of Bruton’s tyrosine kinase (BTK), to resensitize P-gp-overexpressing multidrug-resistant cancer cells to chemotherapeutic agents. Our results demonstrated that branebrutinib is capable of reversing P-gp-mediated MDR at sub-toxic concentrations, most likely by directly inhibiting the drug transport function of P-gp. Our findings were supported by the result of branebrutinib stimulating the ATPase activity of P-gp in a concentration-dependent manner and the in silico study of branebrutinib binding to the substrate-binding pocket of P-gp. In addition, we found that branebrutinib is equally cytotoxic to drug-sensitive parental cell lines and the respective P-gp-overexpressing multidrug-resistant variants, suggesting that it is unlikely that the overexpression of P-gp in cancer cells plays a significant role in reduced susceptibility or resistance to branebrutinib. In summary, we discovered an additional pharmacological action of branebrutinib against the activity of P-gp, which should be investigated further in future drug combination studies. Frontiers Media S.A. 2021-07-19 /pmc/articles/PMC8326665/ /pubmed/34350184 http://dx.doi.org/10.3389/fcell.2021.699571 Text en Copyright © 2021 Wu, Murakami, Wu, Chi, Hsiao, Huang, Hung and Ambudkar. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Wu, Chung-Pu
Murakami, Megumi
Wu, Yu-Shan
Chi, Ya-Chen
Hsiao, Sung-Han
Huang, Yang-Hui
Hung, Tai-Ho
Ambudkar, Suresh V.
Branebrutinib (BMS-986195), a Bruton’s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents
title Branebrutinib (BMS-986195), a Bruton’s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents
title_full Branebrutinib (BMS-986195), a Bruton’s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents
title_fullStr Branebrutinib (BMS-986195), a Bruton’s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents
title_full_unstemmed Branebrutinib (BMS-986195), a Bruton’s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents
title_short Branebrutinib (BMS-986195), a Bruton’s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents
title_sort branebrutinib (bms-986195), a bruton’s tyrosine kinase inhibitor, resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to chemotherapeutic agents
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326665/
https://www.ncbi.nlm.nih.gov/pubmed/34350184
http://dx.doi.org/10.3389/fcell.2021.699571
work_keys_str_mv AT wuchungpu branebrutinibbms986195abrutonstyrosinekinaseinhibitorresensitizespglycoproteinoverexpressingmultidrugresistantcancercellstochemotherapeuticagents
AT murakamimegumi branebrutinibbms986195abrutonstyrosinekinaseinhibitorresensitizespglycoproteinoverexpressingmultidrugresistantcancercellstochemotherapeuticagents
AT wuyushan branebrutinibbms986195abrutonstyrosinekinaseinhibitorresensitizespglycoproteinoverexpressingmultidrugresistantcancercellstochemotherapeuticagents
AT chiyachen branebrutinibbms986195abrutonstyrosinekinaseinhibitorresensitizespglycoproteinoverexpressingmultidrugresistantcancercellstochemotherapeuticagents
AT hsiaosunghan branebrutinibbms986195abrutonstyrosinekinaseinhibitorresensitizespglycoproteinoverexpressingmultidrugresistantcancercellstochemotherapeuticagents
AT huangyanghui branebrutinibbms986195abrutonstyrosinekinaseinhibitorresensitizespglycoproteinoverexpressingmultidrugresistantcancercellstochemotherapeuticagents
AT hungtaiho branebrutinibbms986195abrutonstyrosinekinaseinhibitorresensitizespglycoproteinoverexpressingmultidrugresistantcancercellstochemotherapeuticagents
AT ambudkarsureshv branebrutinibbms986195abrutonstyrosinekinaseinhibitorresensitizespglycoproteinoverexpressingmultidrugresistantcancercellstochemotherapeuticagents